EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Furmonertinib rechallenge after almonertinib-induced interstitial lung disease in EGFR-mutant advanced lung adenocarcinoma: a case report

Qingsen Gao, Dongxing Yang, Jia Wang, Chenxi Wei, Lisha Zhang

Frontiers in Oncology · 18.11.2026 · 16

DOI: 10.3389/fonc.2026.1932940 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 18.11.2026. Verfasst von Qingsen Gao und 4 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

EGFR tyrosine kinase inhibitors (EGFR-TKIs) are effective treatments for EGFR-mutant advanced non-small cell lung cancer, but drug-induced interstitial lung disease (ILD) can interrupt treatment. Resuming EGFR inhibition after ILD presents a difficult decision when chemotherapy is poorly tolerated. Case presentation A 69-year-old woman with stage IVB lung adenocarcinoma harboring an EGFR exon 21 L858R mutation and EGFR amplification discontinued chemotherapy after one cycle because of gastrointestinal intolerance. Almonertinib produced a partial response in the primary lung lesion and brain metastases. After approximately 3 months, she developed cough, chest tightness, hypoxemia, and bilateral pulmonary infiltrates. Evaluation for infection, autoimmune disease, cardiac dysfunction, and tumor progression supported almonertinib-induced ILD. Bronchoalveolar lavage showed 89.0% lymphocytes, with negative pathogen testing. Almonertinib was discontinued, and systemic corticosteroids led to clinical and radiological improvement. Following multidisciplinary review and informed consent, furmonertinib 80 mg once daily was started on November 15, 2025, while she was taking oral methylprednisolone 16 mg daily. The methylprednisolone dose was gradually tapered. Corticosteroids were discontinued on February 15, 2026. At the last follow-up on April 18, 2026, approximately 5 months after initiation of furmonertinib, systemic and intracranial disease remained controlled, with no recurrence or worsening of ILD.

Conclusion

This case documents resumption of EGFR inhibition with an alternative third-generation EGFR-TKI after improvement of almonertinib-induced ILD. Clinical and radiological recovery, prior tumor response, available treatment alternatives, patient preference, and close monitoring informed the decision.

Zitieren

APA

Gao, Q., Yang, D., Wang, J., Wei, C., & Zhang, L. (2026). Furmonertinib rechallenge after almonertinib-induced interstitial lung disease in EGFR-mutant advanced lung adenocarcinoma: a case report. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1932940

Vancouver

Gao Q, Yang D, Wang J, Wei C, Zhang L. Furmonertinib rechallenge after almonertinib-induced interstitial lung disease in EGFR-mutant advanced lung adenocarcinoma: a case report. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1932940

BibTeX
@article{Gao2026,
  author = {Gao, Qingsen and Yang, Dongxing and Wang, Jia and Wei, Chenxi and Zhang, Lisha},
  title = {Furmonertinib rechallenge after almonertinib-induced interstitial lung disease in EGFR-mutant advanced lung adenocarcinoma: a case report},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1932940}
}
Kostenlos starten →